Lee Scott Golden Sells 642 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 642 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $77.48, for a total transaction of $49,742.16. Following the completion of the transaction, the executive vice president directly owned 93,294 shares of the company’s stock, valued at $7,228,419.12. This trade represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Lee Scott Golden also recently made the following trade(s):

• On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $103,113.00.

PTC Therapeutics Trading Down 0.5%

Shares of PTCT traded down $0.39 during trading hours on Thursday, hitting $76.85. The company had a trading volume of 1,625,361 shares, compared to its average volume of 1,684,365. The company has a market capitalization of $6.17 billion, a PE ratio of 8.98 and a beta of 0.49. The company’s fifty day moving average price is $76.43 and its two-hundred day moving average price is $62.53. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same period last year, the business posted ($1.39) earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. Analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors have recently made changes to their positions in PTCT. Smartleaf Asset Management LLC lifted its stake in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. grew its position in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares during the period. Comerica Bank increased its holdings in PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares in the last quarter. IFP Advisors Inc raised its position in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 310 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in shares of PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 295 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PTCT shares. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Wells Fargo & Company boosted their price target on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Morgan Stanley restated an “overweight” rating and issued a $90.00 price objective on shares of PTC Therapeutics in a research note on Thursday. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and upped their target price for the company from $82.00 to $91.00 in a research report on Monday, December 1st. Finally, Citigroup raised their price target on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.